A review of the efficacy and safety of canagliflozin in elderly patients with type 2 diabetes.
Consult Pharm
; 29(5): 335-46, 2014.
Article
en En
| MEDLINE
| ID: mdl-24849690
Palabras clave
ADE = Adverse drug event; AE = Adverse effects; AHA = Antihyperglycemic agent; AUC = Area under the curve; BMI = Body mass index; BP = Blood pressure; CAN = Canagliflozin; CKD = Chronic kidney disease; CV = Cardiovascular; Canagliflozin; DBP = Diastolic blood pressure; Diabetes; Elderly; FPG = Fasting plasma glucose; Geriatrics; HDL-C = High-density lipoprotein cholesterol; ITT = Intention-to-treat; LDL-C = Low-density lipoprotein cholesterol; SBP = Systolic blood pressure; SGLT2 = Sodium glucose cotransporter 2; SGLT2 inhibitor; SU = Sulfonylurea; T2DM = Type 2 diabetes mellitus; Type 2 diabetes; UGT = UDPglucuronosyl transferase; UTI = Urinary tract infection; eGFR = Estimated glomerular filtration rate
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Tiofenos
/
Diabetes Mellitus Tipo 2
/
Inhibidores del Cotransportador de Sodio-Glucosa 2
/
Glucósidos
Tipo de estudio:
Prognostic_studies
/
Systematic_reviews
Límite:
Aged
/
Humans
Idioma:
En
Revista:
Consult Pharm
Asunto de la revista:
FARMACIA
Año:
2014
Tipo del documento:
Article
